Cartessa Aesthetics’ Innovative Multi-Modality Treatment Leads Demand for Non-Invasive Body Procedures

Cartessa Aesthetics recently launched its newest device, PHYSIQ, leading the demand for the latest advancement in body treatments. The company notes PHYSIQ is a novel, dual-modality system that offers deep heat to target tissue and electrical muscle stimulation (EMS) to re-educate muscle – all from one device and in one session. An incredibly versatile device, PHYSIQ’s four applicators can be individually adjusted to tailor the energy and modality delivered to one or more body areas. Providers can select EMS or deep heat only or they have the unique ability to deliver both modalities sequentially within one treatment to maximize results and overall comfort. Treatments are hands-free, require no downtime and can be completely customized to meet each patient’s unique body goals.

Cartessa Aesthetics has made a name for itself by working with leading global aesthetic manufacturers to introduce best-in-class devices to the North American market. With PHYSIQ, aesthetic providers and patients have an optimized body treatment distinct from existing technology in the space.

“Optimizing clinical outcomes while providing best-in-class return on investment to physicians is at the core of Cartessa’s mission statement,” said Gabe Lubin, Cartessa Aesthetics Founder and CEO. “More people are favoring non-invasive procedures, even for treatments that address challenging body aesthetics. Patients want results, but without the pain and downtime that comes with surgery. Being able to offer a more complete patient treatment in a 30-minute session will offer providers a unique competitive advantage in the robust body market.”

The non-invasive body treatment category has erupted in the last decade. From 2011 to 2018 the number of procedures grew four-fold and it is estimated that by 2025, the North American market will hit $1.6 billion growing at an 8% compounded growth rate. PHYSIQ’s low consumable costs, minimal required staff-time and healthy patient demand makes it a premier investment opportunity for aesthetic providers. Sessions range from 24 to 36 minutes and the ability to address multiple body areas with multiple modalities in one session has established PHYSIQ as being truly unique in the body space.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.